Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 3821

BillFederalHouseIn Committee
ADINA Act
About This Bill
Committee
Latest Action · June 6, 2025
Referred to the House Committee on Energy and Commerce.
Congress
119th (2025–2027)
Introduced
June 6, 2025
Cosponsors (20)
12D 8R
View PDF ↗

Summary

Highlight any text to annotate
The ADINA Act (Allergen Disclosure In Non-food Articles Act) requires pharmaceutical manufacturers to clearly label all drugs with ingredients that contain or are derived from major food allergens (such as peanuts, tree nuts, milk, eggs, fish, shellfish, soy, and sesame) or gluten-containing grains like wheat and barley. This requirement applies to all human drugs and aims to protect patients with allergies who might unknowingly consume allergens through their medications. The legislation amends federal labeling rules to consider a drug "misbranded" if it fails to disclose these allergen-containing ingredients on its label. Drug manufacturers must comply with these new labeling requirements no later than two years after the law takes effect, or by an earlier date if the Secretary of Health and Human Services establishes one. The bill addresses a significant public health gap, since many people don't realize that medications can contain food allergens that could trigger allergic reactions.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.